Phaseline

Targets › ATP7B

ATP7B (Copper-transporting ATPase 2): drug programs, companies and trials

5 programs from 5 companies in 5 trials: 4 Phase 1, 1 Phase 3; Metabolic and endocrine, Oncology; next expected readout Feb 2028.

Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. (UniProt, P35670)

Open in Phaseline: the race on ATP7B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OrphalanTETA 4HCl
Copper chelator
ATP7BPhase 3Wilson's DiseaseFeb 2028
Prime MedicinePM577a
Prime editing therapy to correct p.H1069Q mutation in ATP7B gene
ATP7BPhase 1Wilson DiseaseNov 2028
Ultragenyx PharmaceuticalUX701 (rivunatpagene miziparvovec)
Nonreplicating recombinant gene transfer vector delivering functional ATP7B gene
ATP7BPhase 1Wilson DiseaseMar 2029
Vivet Therapeutics SASVTX-801
Replication-deficient recombinant adeno-associated viral vector (rAAV) with liver-tropic c
ATP7BPhase 1Wilson's DiseaseJun 2029
Dartmouth-Hitchcock Medical CenterTetrathiomolybdate (TM)
Copper-lowering agent that forms stable copper-molybdenum clusters, sequestering copper an
ATP7A, ATP7BPhase 1Triple Negative Breast CancerJun 2031

Conditions

Wilson's Disease (2) Wilson Disease (2) Triple Negative Breast Cancer (1)

Modalities

other (2), small molecule (2), mixed (1)

Companies

Vivet Therapeutics SAS (1) Ultragenyx Pharmaceutical (1) Dartmouth-Hitchcock Medical Center (1) Orphalan (1) Prime Medicine (1)

Related targets

ATP7A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.